Insider Selling: BioLife Solutions (NASDAQ:BLFS) EVP Sells 509 Shares of Stock

Key Points

• Aby Mathew, EVP of BioLife Solutions, sold **509 shares** of the company's stock at an average price of **$27.36**, totaling approximately **$13,926.24**.
• Despite the sale, Mathew remains a major stakeholder, owning **350,912 shares** valued at around **$9.6 million**, reflecting a **0.14% decrease** in ownership.
• BioLife Solutions reported a **negative EPS** of **($0.33)** for the last quarter, missing analysts' expectations while achieving **revenue of $25.42 million**, exceeding estimates of **$23.71 million**.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby Mathew sold 509 shares of the stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $27.36, for a total value of $13,926.24. Following the completion of the sale, the executive vice president directly owned 350,912 shares of the company's stock, valued at approximately $9,600,952.32. This represents a 0.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

BioLife Solutions Stock Up 0.9%

Shares of BLFS traded up $0.24 during midday trading on Tuesday, reaching $27.66. 346,859 shares of the stock were exchanged, compared to its average volume of 465,156. BioLife Solutions, Inc. has a 12-month low of $19.10 and a 12-month high of $29.55. The firm has a 50 day simple moving average of $25.21 and a 200-day simple moving average of $23.33. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -230.48 and a beta of 1.95.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). The company had revenue of $25.42 million for the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. BioLife Solutions has set its FY 2025 guidance at EPS. Research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. HC Wainwright restated a "buy" rating and set a $32.00 target price (up previously from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. Stephens assumed coverage on BioLife Solutions in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. Finally, Zacks Research cut BioLife Solutions from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, BioLife Solutions currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.29.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BLFS. Rhumbline Advisers grew its stake in BioLife Solutions by 0.7% in the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock valued at $1,901,000 after acquiring an additional 566 shares during the period. GAMMA Investing LLC grew its stake in BioLife Solutions by 18.6% in the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock valued at $96,000 after acquiring an additional 663 shares during the period. SG Americas Securities LLC grew its stake in BioLife Solutions by 21.6% in the first quarter. SG Americas Securities LLC now owns 19,136 shares of the medical equipment provider's stock valued at $437,000 after acquiring an additional 3,405 shares during the period. Peregrine Capital Management LLC lifted its holdings in shares of BioLife Solutions by 3.5% in the first quarter. Peregrine Capital Management LLC now owns 364,446 shares of the medical equipment provider's stock valued at $8,324,000 after purchasing an additional 12,241 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of BioLife Solutions by 6.2% in the first quarter. Principal Financial Group Inc. now owns 259,488 shares of the medical equipment provider's stock valued at $5,927,000 after purchasing an additional 15,241 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.